Chronic Migraine Implant for Migraine Prevention (RELIEV-CM2)
The purpose of the RELIEV-CM2 study is to evaluate ShiraTronics Migraine Therapy System’s ability to reduce the frequency of headaches for those living with chronic migraine.
Inclusion Criteria:
- You may be eligible for this study if your doctor has diagnosed you with chronic migraine and you meet the following criteria:
- Have had migraine for greater than 12 months
Experience 15 or more headache days per month - Have been treated with or considered treatment with onabolutinum toxin A and a monoclonal antibody against calcitonin gene-related peptide (CGRP) for migraine.
- Have had migraine for greater than 12 months
What to Expect
Neuromodulation therapy delivers small electrical pulses called ‘stimulation’ along a nerve pathway. Applying stimulation to nerve pathways in the head is intended to relieve chronic migraine symptoms
For more information please contact Andrea Bryan 716-250-2017, abryan@dentinstitute.com